Literature DB >> 9316630

Vinorelbine (Navelbine): a third-generation vinca alkaloid.

D R Budman1.   

Abstract

The vinca alkaloids represent one of the oldest classes of antineoplastic agents used in humans with a wide spectrum of activity against both animal and human tumors. These agents are known to inhibit microtubule polymerization. Vinorelbine is a semisynthetic analog that reached clinical trial on the basis of less preclinical evidence of toxicity to neuronal tissue and greater cytotoxic activity in preclinical models than the older compounds of this class. In humans, the clearance of this agent shows a wide variation among subjects with the predominant toxicity being hematological. Significant antitumor activity has been observed in diseases that previously have been shown to respond to vinca alkaloids.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9316630     DOI: 10.3109/07357909709047587

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  10 in total

1.  Synthesis and biological evaluation of 2-amino-1-thiazolyl imidazoles as orally active anticancer agents.

Authors:  Wen-Tai Li; Der-Ren Hwang; Jen-Shin Song; Ching-Ping Chen; Tung-Wei Chen; Chi-Hung Lin; Jiunn-Jye Chuu; Tzu-Wen Lien; Tsu-An Hsu; Chen-Lung Huang; Huan-Yi Tseng; Chu-Chung Lin; Heng-Liang Lin; Chung-Ming Chang; Yu-Sheng Chao; Chiung-Tong Chen
Journal:  Invest New Drugs       Date:  2010-10-02       Impact factor: 3.850

2.  Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.

Authors:  A Halim; H Wahba
Journal:  Med Oncol       Date:  2011-02-25       Impact factor: 3.064

3.  A tubulin binding peptide targets glioma cells disrupting their microtubules, blocking migration, and inducing apoptosis.

Authors:  Raphael Berges; Julien Balzeau; Alan C Peterson; Joel Eyer
Journal:  Mol Ther       Date:  2012-04-10       Impact factor: 11.454

Review 4.  Imidazoles as potential anticancer agents.

Authors:  Imran Ali; Mohammad Nadeem Lone; Haasan Y Aboul-Enein
Journal:  Medchemcomm       Date:  2017-04-13       Impact factor: 3.597

5.  The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.

Authors:  Allison Pledgie-Tracy; Madhavi Billam; Amy Hacker; Michele D Sobolewski; Patrick M Woster; Zhe Zhang; Robert A Casero; Nancy E Davidson
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-30       Impact factor: 3.333

6.  Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells.

Authors:  X M Liu; L G Wang; W Kreis; D R Budman; L M Adams
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

7.  Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane.

Authors:  Jin-Hee Ahn; Sung-Bae Kim; Tae-Won Kim; Sei-Hyun Ahn; Sun-Mi Kim; Jeong-Mi Park; Jung-Shin Lee; Yoon-Koo Kang; Woo Kun Kim
Journal:  J Korean Med Sci       Date:  2004-08       Impact factor: 2.153

Review 8.  Pharmacological factors influencing anticancer drug selection in the elderly.

Authors:  Veena John; Sandeep Mashru; Stuart Lichtman
Journal:  Drugs Aging       Date:  2003       Impact factor: 4.271

9.  Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model.

Authors:  S E Holwell; B T Hill; M C Bibby
Journal:  Br J Cancer       Date:  2001-01       Impact factor: 7.640

10.  Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells.

Authors:  X M Liu; J D Jiang; A C Ferrari; D R Budman; L G Wang
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.